PremiumThe FlyCoinbase, Caterpillar upgraded: Wall Street’s top analyst calls Insmed’s Promising Future: Buy Rating Backed by Breakthrough Treatments and Strategic Expansion Insmed initiated with a Buy at Jefferies PremiumRatingsInsmed’s Promising Pipeline and Strong Financials Justify Buy Rating Insmed’s Strategic Growth and Pipeline Progress Drive Buy Rating Insmed’s Promising Future: Buy Rating Backed by Brensocatib Launch and Strong Clinical Pipeline PremiumThe FlyInsmed says NEJM publishes ‘positive’ results from Phase 3 ASPEN study Insmed’s Brensocatib: A Promising Solution for Bronchiectasis in AATD Patients Insmed’s Strategic Positioning and Growth Potential Justify Buy Rating Despite Leadership Change 
